About Lymphoma | Advocacy | Art | CAM | Clinical trials | Doctors - Experts - Centers | Guidelines at Diagnosis | News
Risk Factors | Side Effects | Statistics | Support | Symptoms | Tests | Treatments | Types of Lymphoma

Search Site         Guidelines at Diagnosis | About Clinical Trials            How to Help!

Patients Against Lymphoma


Hodgkin Lymphoma >  abstracts - ASH 2012

Last update: 11/21/2012

Grouped by:

Reports | Auto SCT | Allo SCT | Novel Agents and Combination  |

Biomarkers - Prognostic / Predictive / Risk Factors
PET imaging | Survivorship

Comments or Questions?

  1. A Web-Based Decision Support Platform to Reduce Non Evidence-Based Treatment of Hodgkin Lymphoma

  2. Interdisciplinary Evidence-Based Guideline for Diagnosis, Therapy and Follow-up of Adult Hodgkin Lymphoma Patients
  3. Clinical and Economic Burden During Hospitalizations Among Cancer Patients with Febrile Neutropenia: Evidence From U.S. Hospitals, 2007-2010


  1. Frontline Therapy with Brentuximab Vedotin Combined with ABVD or AVD in Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma
  2. First Line Treatment of Advanced Stage Hodgkin Lymphoma with Six Cycles of BEACOPPescalated Results in Superior Overall Survival Compared to ABVD: Results of a Network Meta-Analysis Including 10,011 Patients
  3. Early Treatment Intensification in Advanced-Stage High-Risk Hodgkin Lymphoma (HL) Patients, with a Positive FDG-PET Scan After Two ABVD Courses – First Interim Analysis of the GITIL/FIL HD0607 Clinical Trial
  4. Overall Survival Benefit for Patients with Relapsed Hodgkin Lymphoma Treated with Brentuximab Vedotin After Autologous Stem Cell Transplant
  5. Treatment of Stage I-II A Non-Bulky Hodgkin’s Lymphoma (HL): An Individual Patient-Data Comparison of German Hodgkin Study Group (GHSG) HD10 and HD11 Combined-Modality Therapy (CMT) and NCIC Clinical Trials Group (NCIC CTG) HD.6 ABVD Alone
  6. Young Adults Aged 18 to 30 Years with Hodgkin Lymphoma Can Tolerate a Modified Version of the Combined Modality German Paediatric HD95 Protocol with Minimal Neurotoxicity and Excellent Outcome. Results of the UK NCRN 18-30 Study (CRUK/08/012)
  7. Diffuse Large B-Cell Transformation in Nodular Lymphocyte Predominant Hodgkin Lymphoma: Incidence, Risk Factors and Outcomes After a Forty-Year Experience From a Single Institution
  8. Involved Field Radiotherapy Versus No Further Treatment in Patients with Clinical Stages IA and IIA Hodgkin Lymphoma and a ‘Negative’ PET Scan After 3 Cycles ABVD. Results of the UK NCRI RAPID Trial
  9. Long-Term Survival Analyses of an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma
  10. The Outcome of Advanced Stage Nodular Lymphocyte Predominant Hodgkin’s Lymphoma (NLPHL) Compared to Classical Hodgkin’s Lymphoma (CHL): A Matched Pair Analysis
  11. Brentuximab Vedotin (SGN-35) in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies without Prior High-Dose Chemotherapy and Stem Cell Transplantation
  12. Retrospective Analysis of the Safety and Efficacy of Brentuximab Vedotin in Patients Aged 60 Years or Older with Relapsed or Refractory CD30+ Hematologic Malignancies
  13. Predictive Factors for Latency Period and a Prognostic Model for Survival in Patients with Therapy-Related AML


  1. Outcome and Risk Factors of Hodgkin Lymphoma Patients with Relapse or Progression After Autologous Stem Cell Transplant: A Report From the German Hodgkin Study Group (GHSG)
  2. Cytomegalovirus Infection and Lymphopenia Are Associated with Increased Mortality Post Autologous Stem Cell Transplantation
  3. Prognostic Relevance of Dose-Density of DHAP-Reinduction Therapy in Relapsed HL: An Analysis of the German Hodgkin-Study Group (GHSG)
  4. Very High Efficacy of Stem Cell Mobilization Using Intermadiate-Dose Cytosine Arabinoside + G-CSF in Patients with Lymphoid Malignancies, Including Predicted and Proven Poor Mobilizers
  5. Mobilization of Hematopoietic Stem Cells by a Bendamustine-Containing Regimen in Hodgkin’s Lymphoma
  6. Obese Patients Have Improved Survival Following Autologous Hematopoietic Stem Cell Transplantation
  7. Total Lymphoid Irradiation and High-Dose Chemotherapy with Autologous Blood Stem-Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma: Excellent Disease Control and Long-Trm Survival Rates


  1. Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts
  2. Sirolimus, Tacrolimus and Low-Dose Methotrexate Based Graft-Versus-Host Disease (GVHD) Prophylaxis After Non-Ablative or Reduced Intensity Conditioning in Related and Unrelated Donor Allogeneic Stem Cell Transplantation: Decreased Severe Early aGVHD but Persistence of Late Acute Gvhd
  3. Higher Infused Cell Dose Is Associated with a Decreased Risk of Invasive Fungal Infections After Allogeneic Hematopoietic Stem Cell Transplantation
  4. Long Term Follow-up of Allogeneic Transplantation Using BEAM Chemotherapy for Patients with Hodgkin’s Lymphoma Who Relapse After Autologous Transplantation: Importance of Minimal Residual Disease At Transplant
  5. Donor Lymphocyte Infusions (DLI) Following Haplo Bone Marrow Transplantation (hBMT) with High-Dose of Cyclophosphamide Post-Transplant As Gvhd Prophylaxis
  6. Donor Lymphocyte Infusion for Relapsed Hematological Malignancies After Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial CD3+ T Cell Dose
  7. Full Dose Treosulfan Based Reduced Toxicity Conditioning Regimen in Allogeneic Stem Cell Transplantation: Results in 123 Patients
  8. Risk Factors of GANCICLOVIR–RELATED Neutropenia After Allogeneic STEM CELL Transplantation: A Retrospective Monocenter Study On 547 Patients
  9. Early Reconstitution of T-Cell Immunity to CMV After HLA-Haploidentical Hematopoietic Stem Cell Transplantation Is a Strong Surrogate Biomarker for Lower Non-Relapse Mortality Rates
  10. CD30-Targeted Therapy with Brentuximab Vedotin Combined with Donor Lymphocyte Infusions Induce Sustained Clinical Remissions and Tumor Specific Immunity in a Series of Patients with Relapsed Hodgkin Lymphoma After Allogeneic Stem Cell Transplantation
  11. Bendamustine for Relapsed/Refractory Classical Hodgkin Lymphoma After High Dose Chemotherapy and or Allogeneic Transplant: A Study of Fondazione Italiana Linfomi (FIL)



  1. The 2nd Generation Proteasome Inhibitor, MLN2238: Potent Induction of Cell Death in T-Cell Lymphoma (TCL) and Hodgkin Lymphoma (HL) Cell Lines and in Two Human Lymphoma Xenograft Models
  2. A Phase 2 Multicenter Study of Continuous Dose Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma
  3. CSF1R Inhibition by PLX3397 in Patients with Relapsed or Refractory Hodgkin Lymphoma: Results From a Phase 2 Single Agent Clinical Trial
  4. Darinaparsin in T-Cell Lymphoma (TCL) and Hodgkin Lymphoma (HL) Cells Lines and SCID Xenograft Mouse Models: Single-Agent Activity and Synergistic Cell Death Combined with a PI3K/mTOR Inhibitor
  5. Mast Cells As a Therapeutic Target for Hodgkin Lymphoma: Bortezomib Inhibits Mast Cell-Induced Modification of the Tumor Microenvironment
  6. Everolimus for Relapsed/Refractory Classical Hodgkin Lymphoma: Multicenter, Open-Label, Single-Arm, Phase 2 Study
  7. Abexinostat (S78454 / PCI-24781), an Oral Pan-Histone Deacetylas (HDAC) Inhibitor in Patients with Refractory or Relapsed Hodgkin's Lymphoma, Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. Results of a Phase I Dose-Escalation Study in 35 Patients
  8. The histone Deacetylase Inhibitor Givinostat in Combination with Sorafenib Induces Reactive Oxygen Species (ROS) Generation and Exerts Potent Antitumor Effects in NOD/SCID Mice with Hodgkin Lymphoma Cell Line Xenografts
  9. MLN4924, an Investigational Small Molecule Inhibitor of NEDD8-Activating Enzyme (NAE), Inhibits NF-κB Activity and Induces G1 Cell Cycle Arrest and Apoptosis in Pre-Clinical Models of Hodgkin Lymphoma (HL)
  10. SL-101, a Novel Monoclonal Antibody-Conjugate That Targets Interleukin-3 Receptor Alpha (CD123), Possesses Preclinical Anti-Tumor Activity Against Hodgkin’s Lymphoma
  11. A Phase I Trial of the Histone Deacetylase (HDAC) Inhibitor, Panobinostat, in Combination with Lenalidomide in Patients with Relapsed/Refractory Hodgkin’s Lymphoma (HL)



  1. FDG-PET/CT Metabolic Tumor Volume: A New Prognostic Marker in Hodgkin Lymphoma?
  2. Metabolic Tumor Volume Is an Independent Prognosis Factor Predicting patient’s Outcome in Hodgkin Lymphoma
  3. Interim Analysis of the Randomized Eortc/Lysa/Fil Intergroup H10 Trial On Early PET-Scan Driven Treatment Adaptation in Stage I/II Hodgkin Lymphoma
  4. The Prognostic Value of Interim PET Scan in Patients with Classical Hodgkin Lymphoma
  5. Relative Reduction of Residual Tumor Improves Outcome Prediction of PET After Effective Chemotherapy for Patients with Advanced Stage Hodgkin Lymphoma
  6. Positron Emission Tomography Combined with Computed Tomography (PET-CT) Should Substitute Classical CT in the Initial Staging of Hodgkin Lymphoma (HL)
  7. Interim [18F]Fluorodeoxyglucosepositron Emission Tomography Suvmax Reduction Is Superior to Visual Analysis to Predict Early patient’s Outcome in Hodgkin Lymphoma
  8. Disease Extent in Newly Diagnosed Hodgkin Lymphoma: A Comparison of CT and PET/CT Staged Patients
  9. 18f-FDG (FDG) PET Five-Point Visual and Quantitative SUV-Based Assessment and Prognosis in Pediatric Hodgkin Lymphoma (HL). A Preliminary Retrospective Analysis of Children’s Oncology Group (COG) AHOD0031
  10. Semi-Quantitative Evaluation of Pre-Transplant FDG-PET in Relapsed and Refractory Hodgkin Lymphoma
  11. How Does PET/CT Help in Selecting Therapy for Patients with Hodgkin Lymphoma?



  1. Heritability of Hematologic Neoplasms in Twins: An Update
  2. New Insights in the Biology of Hodgkin Lymphoma
  3. Epstein-Barr Virus Status Correlates with Composition and Prognostic Impact of the Tumor Microenvironment in Classical Hodgkin Lymphoma
  4. Clinical Significance of Tumor-Associated Macrophages in Early-Stage Hodgkin's Lymphoma
  5. Strong HLA Class I Expression Is Positively Correlated with the Number of PML Nuclear Bodies and Negatively with the Percentage of SATB1 Positive HRS Cells in EBV+ Classical Hodgkin Lymphoma (cHL)
  6. Exploring the HLA-A Associations in EBV-Associated Classical Hodgkin Lymphoma : HLA-A Genotype Modifies the HLA-A*02:01 Restricted Cytotoxic T-Cell and Cytokine Response to EBV
  7. Discrimination of an Early Unfavorable Risk Group Has Significant Impact On Treatment Outcome in Early-Stage Hodgkin Lymphoma: An Analysis of International Staging Definitions and Risk Factors
  8. Fecal Microbiota Diversity in Survivors of Adolescent/Young Adult Hodgkin Lymphoma
  9. Clinical Features and Outcome in Newly Diagnosed Hodgkin Lymphoma Patients Presenting with PET/CT-Ascertained Focal Skeletal Lesions
  10. HLA Associated Susceptibility to EBV+ Hodgkin Lymphoma: No Correlation with Infectious Mononucleosis or Number of Circulating EBV+ B Cells
  11. EBV-Specific Micro-RNA Via Exosome: A Key Inter-Cellular machinery between EBV+ Tumor and Tumor-Surrounding Immune Cells?S
  12. HLA-A*02:01 Is Associated with Inferior Overall Survival in EBV-Associated Classical Hodgkin Lymphoma
  13. Serum CD163 and TARC in Combination As Disease Response Biomarkers in Classical Hodgkin Lymphoma
  14. Molecular Determinants of Bendamustine (BDM) Toxicity towards Hodgkin (H) and Reed-Sternberg (RS) Cell Lines From Hodgkin Lymphoma (HL)
  15. Prognostic Value of Six Germline Single Nucleotide Polymorphisms At the REL, HLA-DRA, GATA3 and PVT1 Loci Identified in a Classical Hodgkin Lymphoma Genome-Wide Association Study: A Meta-Analysis of 601 Patients for Progression-Free Survival From Two Independent Studies
  16. Prognostic Factors in Patients with HIV-Associated Hodgkin Lymphoma: An Analysis of 199 Cases
  17. Peripheral Blood Absolute Lymphocyte/Monocyte Ratio Recovery During ABVD Treatment Cycles Predicts Clinical Outcomes in Classical Hodgkin Lymphoma (HL)
  18. Peripheral Blood Absolute Lymphocyte/Monocyte Ratio At Diagnosis Is Independent of the Interim Positron-Emission Tomography in Predicting Progression-Free Survival and Time to Progression in Classical Hodgkin Lymphoma (HL)
  19. Baseline Fibroblast Growth Factor-2 (FGF2) and Syndecan-1 (SDC1) Expression in Circulating CD15+/CD30+ Cells Correlate with Very Poor Outcome in Hodgkin Lymphoma
  20. Galectin-1 Serum Levels Reflect Tumor Burden and Adverse Clinical Features in Hodgkin Lymphoma
  21. Expression, Prognostic Value and Function of IGF1R in Hodgkin Lymphoma



  1. Factors Affecting Quality of Life During and After Stem Cell Transplantation in Long Term Survivors – Comparison of Autologous and Allogeneic Stem Cell Transplantation
  2. LONG-TERM Risk of Late Effects After Treatment for EARLY-STAGE HODGKIN’S Lymphoma (HL)
  3. Positive Maternal-Fetal Outcomes with Treatment of Lymphoma During Pregnancy: UT MD Anderson Cancer Center Prospective Experience
  4. Gonadal Function in Survivors After Hodgkin Lymphoma (HL) Treatment within the German Hodgkin Study Group (GHSG) HD13-15 Trials
  5. Is Recovery of Gonadal function possible in Very Long-Term Adult Male Survivors of Hodgkin's Lymphoma?
  6. 723. Clinical Allogeneic and Autologous Transplantation - Late Complications and Approaches to Disease Recurrence: Poster III




See also Other Ways to Help


Disclaimer:  The information on Lymphomation.org is not intended to be a substitute for 
professional medical advice or to replace your relationship with a physician.
For all medical concerns,  you should always consult your doctor. 
Patients Against Lymphoma, Copyright © 2004,  All Rights Reserved.